AbbVie has announced that it’s partnering with Rockville, Md.-based Regenxbio on a gene therapy candidate for eye diseases.

The two companies said that they will work together to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases.

AbbVie will pay Regenxbio $370 million upfront with the potential for up to $1.38 billion in additional milestone payments.

Under the collaboration, Regenxbio will complete ongoing trials of RGX-314, and the two companies will work together on and share costs for additional trials, including a planned second trial evaluating subretinal delivery for the treatment of wet AMD.